IMC-EB10: Phase I started

Last quarter, Eli Lilly's ImClone Systems Inc. unit began an open-label, dose-escalation, U.S. Phase I trial to evaluate 5, 10, 20 and 30 mg/kg IV IMC-EB10 in 30 patients. The trial start triggered a...